SurModics, Inc. (NASDAQ:SRDX) CEO Gary R. Maharaj sold 5,000 shares of SurModics stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $59.35, for a total transaction of $296,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NASDAQ:SRDX opened at $59.90 on Friday. The firm has a market capitalization of $761.54 million, a P/E ratio of 122.24, a P/E/G ratio of 71.05 and a beta of 0.89. SurModics, Inc. has a 12-month low of $25.00 and a 12-month high of $82.35.
SurModics (NASDAQ:SRDX) last released its quarterly earnings data on Friday, November 9th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $23.04 million during the quarter, compared to the consensus estimate of $22.54 million. SurModics had a negative net margin of 5.48% and a positive return on equity of 6.12%. On average, analysts expect that SurModics, Inc. will post 0.08 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the business. O Shaughnessy Asset Management LLC acquired a new position in SurModics in the third quarter worth $101,000. C M Bidwell & Associates Ltd. acquired a new position in SurModics in the third quarter worth $109,000. Quantbot Technologies LP acquired a new position in SurModics in the third quarter worth $112,000. Piedmont Investment Advisors LLC acquired a new position in SurModics in the second quarter worth $170,000. Finally, Ibex Investors LLC acquired a new position in SurModics in the third quarter worth $208,000. 84.82% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://dakotafinancialnews.com/2018/12/07/surmodics-inc-srdx-ceo-gary-r-maharaj-sells-5000-shares.html.
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.